🔥 Absolute masterclass @philseo in the Clinical Year in Review #ACR23 ➡️ Certain subpopulations have lower risk of AE with Tofacitinib ➡️ Knee OA 📈 75% by 2050 ➡️ Exciting novel approaches in Rx of IA in development ➡️Better clinical trial endpoints needed for SLE https://t.co/5cjbZLPsCM